Clinical Variant of Guillain-Barre Syndrome With Prominent Facial Diplegia After AstraZeneca Coronavirus Disease 2019 Vaccine

J Clin Neuromuscul Dis. 2021 Dec 1;23(2):115-116. doi: 10.1097/CND.0000000000000383.

Authors

Anca Badoiu¹, Olivier Moranne², Sarah Coudray³, Ioana Maria Ion¹

Affiliations

¹ Departments of Neurology.
² Nephrology.
³ Electrophysiology, Nîmes University Hospital, France.

PMID: 34808658
DOI: 10.1097/CND.0000000000000383

No abstract available

MeSH terms

COVID-19 / prevention & control*
COVID-19 Vaccines
ChAdOx1 nCoV-19 / administration & dosage
ChAdOx1 nCoV-19 / adverse effects*
Facial Paralysis / etiology*
Female
Guillain-Barre Syndrome* / etiology
Humans
Middle Aged
SARS-CoV-2

Substances

COVID-19 Vaccines
ChAdOx1 nCoV-19